Clinical trial
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients With Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
NCT03992430 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-label Dose Escalation, in Patients With Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- July 13, 2020
- Completion date
- October 31, 2026
- Enrollment
- 160 (actual)
- Sites
- 59
Conditions
As the registry lists them; a condition with its own page is linked.